Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger’s Novel Early Cancer Detection Platform

CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection. The Cancer ORigin Epigenetics- Harbinger Health (CORE-HH) study plans … [Read more…]

Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market

RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. MDSS will support early-stage biomedical startups with direct investment, access to powerful Azure Cloud computing and opportunities … [Read more…]

Vizient Announces Strategic Partnership with Supply Risk Solutions

Partnership enhances transparency between providers and suppliers IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. announced today it has entered into a strategic partnership with Supply Risk Solutions to provide a database platform for the collection of healthcare supply pedigree data. The partnership will provide automated supply chain disruption monitoring and risk prevention for Vizient members and is the … [Read more…]

RISCS, Inc. Joins End Drug Shortages Alliance

DENVER–(BUSINESS WIRE)–#drugshortages—RISCS, Inc. announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance (EDSA) provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care. “We … [Read more…]

ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M

– Series B extension co-led by AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer, with participation from Amgen Ventures. Adds to Existing Investors, including Pfizer Ventures, EcoR1 Capital and Sanofi Ventures. – – Proceeds to expand and diversify platform and pipeline to include mRNA and gene correction therapeutics for central nervous system, … [Read more…]

OrbitalRX Joins End Drug Shortages Alliance

WINSTON-SALEM, N.C.–(BUSINESS WIRE)–#drugshortagemanagement–OrbitalRX announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care. “Drug shortages … [Read more…]

The Worldwide Pharmaceutical Contract Development & Manufacturing Industry is Expected to Reach $226 Billion by 2029 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Contract Development & Manufacturing Market by Service, End User – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 7.5% from 2022 to 2029 to reach $226.35 billion by 2029. Following extensive secondary and primary … [Read more…]

2022 Insights on the Baculoviral IAP Repeat Containing Protein 5 Drugs in Development – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Baculoviral IAP Repeat Containing Protein 5 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. This report provides in depth analysis on Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted pipeline … [Read more…]

Global Prefilled Syringes Market to 2028 – Collaborations and Investments to Open an Array of Opportunities for the Market to Flourish – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Prefilled Syringes Global Market – Forecast To 2028” report has been added to ResearchAndMarkets.com’s offering. The prefilled syringes global market is expected to grow at a high single digit CAGR to reach $10,273.8 million by 2028. The prefilled syringes global market is categorized into various market segments based on the material, design, closure … [Read more…]

Avacta Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin

LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from … [Read more…]